Sodegaura, Japan

Yasuko Watanabe

This inventor holds 1 USPTO granted patent. Top assignee: Nihon Medi-Physics Company, Limited. Active years: 2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yasuko Watanabe. Retrieved from https://idiyas.com/inventor/yasuko-watanabe-d1m9sams

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yasuko Watanabe: Innovator in Radiopharmaceuticals

Introduction

Yasuko Watanabe is a prominent inventor based in Sodegaura, Japan. She has made significant contributions to the field of radiopharmaceuticals, particularly through her innovative work on bisphosphonic acid derivatives.

Latest Patents

Watanabe holds a patent for a bisphosphonic acid derivative and a compound thereof labeled with a radioactive nuclide. This invention is crucial for advancements in medical imaging and treatment.

Career Highlights

Watanabe is associated with Nihon Medi-Physics Company, Limited, where she has been instrumental in developing new technologies in the medical field. Her work has garnered attention for its potential applications in diagnostics and therapy.

Collaborations

Watanabe collaborates with notable colleagues, including Osamu Ito and Nobuhiko Kanazashi. Their combined expertise enhances the innovative capacity of their projects.

Conclusion

Yasuko Watanabe's contributions to the field of radiopharmaceuticals exemplify the impact of innovative thinking in medicine. Her work continues to pave the way for advancements that can improve patient care and diagnostic accuracy.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…